Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Hib-MenC vaccine with Priorix versus Meningitec plus Hiberix with Priorix in toddlers
2011-005032-26Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in meningococcal disease and Haemophilus influenzae type b disease (Hib) comparing Hib-MenC-TT + Priorix with Meningitec + Hiberix + Priorix (2 arms). Primary endpoints: SBA-MenC titre and Anti-PRP concentration.
02
Drugs
Hib-MenC-TTmeasles, mumps and rubella vaccine (live)Meningococcal group C polysaccharide conjugate vaccinehaemophilus influenzae type b vaccine
03
Conditions
meningococcal diseaseHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2011-005032-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005032-26.